Application of intrathecal trastuzumab for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer

1138 Background: When the humanized anti-HER2 monoclonal antibody trastuzumab is given intravenously, very little reaches the cerebrospinal fluid (CSF). Thus, carcinomatous meningitis may occur in ...